Efficacy of intravitreal bevacizumab for zone‐<scp>II</scp> retinopathy of prematurity

Abstract

Recurrence of neovascularization with bevacizumab monotherapy seems to be higher than that with conventional laser therapy among infants with Type 1 ROP in zone II ROP but reinjection of bevacizumab causes regression in most recurrent cases.